BACKGROUND: Pulmonary arterial hypertension (PAH) remains a poorly understood and
frequently lethal disease with few treatment options. METHODS: We conducted a placebo …

Objective: Pulmonary hypertension may be encountered in the intensive care unit in patients
with critical illnesses such as acute respiratory distress syndrome, left ventricular …

The association between autoimmunity and pulmonary arterial hypertension (PAH) has
been appreciated for> 40 yrs, but how autoimmune injury might contribute to the …

Idiopathic pulmonary arterial hypertension (PAH) is a fatal and progressive disease.
Sustained vasoconstriction due to pulmonary arterial smooth muscle cell (PASMC) …

Deficient angiogenesis and systemic inflammation could be involved in the pathophysiology
of chronic thromboembolic pulmonary hypertension (CTEPH). We aimed to characterise the …

Pulmonary hypertension (PH) is a progressive, lethal lung disease characterized by
pulmonary artery SMC (PA-SMC) hyperplasia leading to right-sided heart failure. Molecular …

Rationale: Inflammatory cytokines may affect pulmonary vascular remodeling in idiopathic
pulmonary arterial hypertension (IPAH). CC chemokine ligand 2 (CCL2) is synthesized by …

Background—Severe pulmonary hypertension is a disabling disease with high mortality,
characterized by pulmonary vascular remodeling and right heart hypertrophy. Using wild …

Abstract Purpose of Review This review focuses on the therapeutic management and
individualized approach to Group 1 pulmonary arterial hypertension (PAH), utilizing Food …

Mutations in bone morphogenetic protein (BMP) receptor II (BMPRII) are associated with
pulmonary artery endothelial cell (PAEC) apoptosis and the loss of small vessels seen in …